Wyeth Re-enters Appetite Suppression Game With Thiakis Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Metabolic disorders is one of six focus areas targeted by Wyeth’s new discovery plan.
You may also be interested in...
Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist
Boehringer wins global rights to Zealand's Phase I-ready novel diabetes compound, pledging €20 million during 2011.
Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist
Boehringer wins global rights to Zealand's Phase I-ready novel diabetes compound, pledging €20 million during 2011.
Imperial Innovations Raises £140 Million To Invest In University Spin-Outs
The AIM-listed tech transfer group will increase its early-stage investments in spin-outs from Imperial College and three other top UK universities